DE2559384A1 - Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics - Google Patents
Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmeticsInfo
- Publication number
- DE2559384A1 DE2559384A1 DE19752559384 DE2559384A DE2559384A1 DE 2559384 A1 DE2559384 A1 DE 2559384A1 DE 19752559384 DE19752559384 DE 19752559384 DE 2559384 A DE2559384 A DE 2559384A DE 2559384 A1 DE2559384 A1 DE 2559384A1
- Authority
- DE
- Germany
- Prior art keywords
- caffeine
- nicotinic acid
- acid amide
- nicotinamide
- medicaments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 title claims abstract description 66
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title claims abstract description 43
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 229960001948 caffeine Drugs 0.000 title claims abstract description 33
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 235000005152 nicotinamide Nutrition 0.000 title claims abstract description 19
- 239000011570 nicotinamide Substances 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 235000013305 food Nutrition 0.000 title claims abstract description 4
- 239000002537 cosmetic Substances 0.000 title abstract description 3
- 229960003966 nicotinamide Drugs 0.000 title abstract 2
- 230000001988 toxicity Effects 0.000 title abstract 2
- 231100000419 toxicity Toxicity 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 2
- 230000000378 dietary effect Effects 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract description 3
- 239000002775 capsule Substances 0.000 abstract description 3
- 235000015203 fruit juice Nutrition 0.000 abstract description 3
- 239000008101 lactose Substances 0.000 abstract description 3
- 235000009508 confectionery Nutrition 0.000 abstract description 2
- 210000002216 heart Anatomy 0.000 abstract description 2
- 210000000936 intestine Anatomy 0.000 abstract description 2
- 230000007935 neutral effect Effects 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 235000014101 wine Nutrition 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 1
- 235000020965 cold beverage Nutrition 0.000 abstract 1
- 235000013409 condiments Nutrition 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- LGSQXYMSKLPKOK-UHFFFAOYSA-N NC(=O)C1=CC=CN=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C Chemical compound NC(=O)C1=CC=CN=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C LGSQXYMSKLPKOK-UHFFFAOYSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007786 learning performance Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940124641 pain reliever Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ASMSSJWNOWPYOD-UHFFFAOYSA-N 4-[(3,7-dimethyl-2,6-dioxopurin-1-yl)methyl]pyridine-3-carboxamide Chemical compound O=C1C=2N(C)C=NC=2N(C)C(=O)N1CC1=CC=NC=C1C(N)=O ASMSSJWNOWPYOD-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 229940015412 caffeine 25 mg Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000015122 lemonade Nutrition 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/045—Organic compounds containing nitrogen as heteroatom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12H—PASTEURISATION, STERILISATION, PRESERVATION, PURIFICATION, CLARIFICATION OR AGEING OF ALCOHOLIC BEVERAGES; METHODS FOR ALTERING THE ALCOHOL CONTENT OF FERMENTED SOLUTIONS OR ALCOHOLIC BEVERAGES
- C12H1/00—Pasteurisation, sterilisation, preservation, purification, clarification, or ageing of alcoholic beverages
- C12H1/12—Pasteurisation, sterilisation, preservation, purification, clarification, or ageing of alcoholic beverages without precipitation
- C12H1/14—Pasteurisation, sterilisation, preservation, purification, clarification, or ageing of alcoholic beverages without precipitation with non-precipitating compounds, e.g. sulfiting; Sequestration, e.g. with chelate-producing compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Coffein-Kombination Caffeine combination
Die Erfindung umfaßt eine Coffein-Kombination aus Coffein und Nikotinsäureamid.The invention includes a caffeine combination of caffeine and nicotinic acid amide.
Coffein ist bereits mit zahlreichen anderen Substanzen kombiniert worden, so insbesondere mit Schmerzstillungsmitteln und mit kreislaufaktiven. Nun haben alle diese Kombinationen keinen Einfluß auf die physikalischen oder biochemischen Eigenschften des Coffeins bewirkt. Coffein sollte in all den bisher bekannzen Kombinationen zunächst nur die Wirkung bekannter Schmerzstillungs- oder Kreislaufmittel verbessern, rnehr nicht. Vor allem wurde ei all den Kombinationen niemals eine Verbesserung der physikalischen oder gar phar kologischen Eigenschaften des Coffeins erstrebt.Caffeine is already combined with numerous other substances especially with pain relievers and active circulatory drugs. so none of these combinations have any influence on the physical or biochemical Caffeine's properties. Caffeine should be used in all of the previously known combinations initially only improve the effect of known pain relievers or circulatory drugs, no more. Above all, none of the combinations was ever an improvement strives for the physical or even pharmaceutical properties of caffeine.
Demgemäß wurde gefunden, daß eine Kombination des Coffeins mit Nikotinsäureamid 1. eine Löslichkeit des Coffoins in Wasser mit neutralem pH bewirkt, eine Verbesserung der pharmakologischen Eijenschaften des Coffeins ergibt. insbesondere ergibt sich durch die Kombination ein leistungssteigernder Effekt, wie ein solcher bei geringer Toxizität von keinem bisher bekannten Stoff gegeben wird.Accordingly, it has been found that a combination of the caffeine with nicotinic acid amide 1. A solubility of the coffoin in water with neutral pH causes an improvement the pharmacological properties of caffeine. in particular it results through the combination, a performance-enhancing effect, such as one with low Toxicity is not given by any previously known substance.
Für die Kombinution eignen sich Mischverhältnisse von einem Teil Coffein auf 0,1 bis 5 Teile Nikotinsäureamid, zweckmäßig jedoch : 1, also ein Teil Coffein und ein Teil hsikotinsqureamid.Mixing ratios of one part of caffeine are suitable for the combination to 0.1 to 5 parts of nicotinic acid amide, expediently however: 1, that is to say one part of caffeine and part of hsikotinsqureamid.
Erfindungsgemäß soll aber diese Kombination durch Mischungsgrenzen nicht begrenzt werden. Demgemaß ist Gegenstand der Erfindung Präparate, welche Coffein und Nikotinsäureamid besitzen. Es können einer solchen Kombination noch Alalgetika, Kreislaufmittel, Vitamine oder Traubenzucker, Lezithin und ähnliche Stoffe zugesetzt werden. Die Kombination kann in Erfindungsgetränken, Weinen, Fruchtsäften, E3onbon und dergleichen angewendet und in konventioneller weise zubereitet werden.According to the invention, however, this combination should be limited by mixing limits not be limited. Accordingly, the invention relates to preparations which contain caffeine and nicotinic acid amide. Such a combination can also contain alalgesics, Circulatory drugs, vitamins or glucose, lecithin and similar substances added will. The combination can be used in invention drinks, wines, fruit juices, candy and the like applied and prepared in a conventional manner will.
In dieser Rinsicht obliegt der Erfindung keine begrenzung.In this regard, the invention is not limited.
Die Oberlegenheit und Reuigkeit der Erfindung zeigt sich un folgenden experimenten: @@gr @@@zen und 10 gr Nikotinsäureamid werden gut gemischt, dem für @ ml Wasser hinzu, erwärmt kurz und erhalt eine klare Lösungs anlichniges Coffein ist nicht wasserlöslich, was wie folgt gezeizeight wird: 10 gr Coffein werden mit 0 ml Wasser versetzt, Man erhält eine Suspension, die auch beim Erwärmen nicht in Lösung geht.The superiority and repentance of the invention are shown in the following Experiments: @@ gr @@@ zen and 10 gr nicotinic acid amide are mixed well for Add @ ml of water, heat briefly and obtain a clear solution of similar caffeine is not soluble in water, which is shown as follows: 10 grams of caffeine are added 0 ml of water are added. A suspension is obtained which, even when heated, does not turn into Solution works.
Nun fügt man nach Erkalten portionsweise 10 gr Nikotinsäureamid hinzu. Bei einem jedoch Zusatz von Nikotinsäureamid löst sich Coffein teilweise auf. Die Lösung ist bei 5-6 gr Nikotinsaureamid vollständig.Now, after cooling, 10 g of nicotinic acid amide are added in portions. However, when nicotinic acid amide is added, caffeine partially dissolves. the Solution is complete at 5-6 grams of nicotinic acid amide.
Mit einer Mischung aus einem Teil Coffein und einem Teil Nikotinsaureamid
wurden folgenden Tierversuche durchgeführt: a) akute Toxizität in mg/kg Maus
Coffein stelgert in einer Besis von 5 mg/kg die Lernleistung nur um 12 gr, Coffein-Nikotinsäureamid jedoch um 65 gr. At a level of 5 mg / kg, caffeine only increases learning performance around 12 gr, but caffeine nicotinic acid amide around 65 gr.
d) Einfluß auf Herz- und Kreislauf.d) Influence on the cardiovascular system.
Coffein hat in einer dosis von 2,5 bis 10 mg/kg Hund einen Biphasischen Einfluß auf Blutdruck. Es kommt zuerst zu einem Blutdruckanstieg, dann zu einem Abfell. Caffeine is biphasic at a dose of 2.5 to 10 mg / kg dog Influence on blood pressure. There is an increase in blood pressure first, then one Abfell.
Coffein-Nikotinsäureamid hat in Dosen von 1,5 bis 30 mg/kg Hund ke@@ Ein@fin auf Blutdurck.Caffeine nicotinic acid amide has doses of 1.5 to 30 mg / kg dog ke @@ An @ fin on blood pressure.
@ise folgensche Wirkung der neuen Kombination war in keiner weise vorherzusehen gewesen. Im Gegenteil, bei der bekannten unangenehmen Wirkung des Coffeins auf Herz, Magen und Darm war bei einer Wesserlöslichmachung und einer jeden Kombination, die Wasserlöslichkeit bewirken könnte, mit den bekannten Herzsensaionen und Hitzewalliungen zu rechnen. Solche traten auch beim Menschen in Versuchen emnach ergibt die Kombination Coffein-Nikotinsäureamid ein Arzneimittel mit einer nicht zu erwartenden Wirkung einerseits und einem Fortschritt, wie ein solcher nicht zu erwarten gewesen ist.The following effect of the new combination could not have been foreseen in any way. On the contrary, with the well-known unpleasant effects of caffeine on the heart, stomach and intestines, the well-known cardiac sensations and hot flashes were to be expected with water-solubilization and any combination that could cause water-solubility. Such tests have also occurred in humans Accordingly, the combination of caffeine-nicotinic acid amide results in a medicament with an unexpected effect on the one hand and a progress that could not have been expected.
Diese Kombination soll als Arzneimittel in der Haman- und Veterinärmedizin, in der und Nachrungsmittelindustrie in konventionell bekannten Zubereitungen Anwendung finden.This combination is intended as a medicinal product in Haman and veterinary medicine, in the and food industry are used in conventionally known preparations.
demnach ist das wesen der Erfindung: Arzneimittel, Diätetika, Nahrungs- und Gehubmittel, kosmetische Mittel, die Nikotinsäureamid und Coffein in solchen Verhältnissen enthalten, daß die Kombination vollständig oder teilweise wasserlöslich ist.Accordingly, the essence of the invention is: Medicines, dietetics, nutritional and sweeteners, cosmetic agents that contain nicotinic acid amide and caffeine in such Contains proportions that the combination is completely or partially water-soluble is.
Es soll an einigen beispielen die Ausführung der Erfindung gezeigt werden, ohne daß dieselben in den Grundgedanken eingeschränkt wird.The implementation of the invention is intended to be shown by means of a few examples without their basic ideas being restricted.
Beispiel 1: 10 gr Coffein und 10 gr Nikotinsäureamid werden miteinander gemischt.Example 1: 10 grams of caffeine and 10 grams of nicotinic acid amide are mixed together mixed.
1 gr des Gemisches sind mit @ ml Wasser glatt löslich, pH 6,7 bis 7.1 gr of the mixture is readily soluble with @ ml of water, pH 6.7 to 7th
Diese Lösung kann für Injektionszubereitungen dienen, mit Fruchtsäften, Sirupen oder Getranken verdünnt werden oder als Limonaden zubereitet werden.This solution can be used for injection preparations, with fruit juices, Syrups or beverages can be diluted or prepared as lemonades.
Beispiel 2: Tabletten Coffein 25 mg Nikotinsäureamid 25 mg Lactose 198 mg Getreidestärke 25 mg Talk 15 mg Magnesiumstearat 1 mg 290 mg Die bestandteile werden in bekannter Weise und i-rozedur zu Tabletten verarbeitet.Example 2: tablets caffeine 25 mg nicotinic acid amide 25 mg lactose 198 mg corn starch 25 mg talc 15 mg magnesium stearate 1 mg 290 mg the ingredients are processed into tablets in a known manner and procedure.
Beispiel 3: Kapseln Coffein 50 m Nikotinsäureamid 100 mg Lactose und Zusätze 200 mg Die Bestandteile werden gemischt und in Kapseln gefüllt.Example 3: Capsules caffeine 50 m nicotinic acid amide 100 mg lactose and Additions 200 mg The ingredients are mixed and filled into capsules.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752559384 DE2559384A1 (en) | 1975-12-31 | 1975-12-31 | Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752559384 DE2559384A1 (en) | 1975-12-31 | 1975-12-31 | Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2559384A1 true DE2559384A1 (en) | 1977-07-14 |
Family
ID=5965992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752559384 Withdrawn DE2559384A1 (en) | 1975-12-31 | 1975-12-31 | Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE2559384A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833147A (en) * | 1986-03-17 | 1989-05-23 | Henkel Kommanditgesellschaft Auf Aktien | Sebosuppressive compositions and method for suppressing sebaceous gland activity |
| GB2285578A (en) * | 1993-12-22 | 1995-07-19 | Leilani Lea | Beverages containing added guaranine |
| US5900416A (en) * | 1996-02-01 | 1999-05-04 | Anthea Enterprises Incorporated | Aqueous caffeine dosage forms |
| US6290994B1 (en) | 1995-04-12 | 2001-09-18 | Decox, S.L. | Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity |
| WO2018001899A1 (en) * | 2016-06-30 | 2018-01-04 | L'oreal | Liquid mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and xanthine compound |
-
1975
- 1975-12-31 DE DE19752559384 patent/DE2559384A1/en not_active Withdrawn
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4833147A (en) * | 1986-03-17 | 1989-05-23 | Henkel Kommanditgesellschaft Auf Aktien | Sebosuppressive compositions and method for suppressing sebaceous gland activity |
| GB2285578A (en) * | 1993-12-22 | 1995-07-19 | Leilani Lea | Beverages containing added guaranine |
| US6290994B1 (en) | 1995-04-12 | 2001-09-18 | Decox, S.L. | Beverage containing caffeine or theobromine and vinpocetine citrate for stimulating cerebral activity |
| US5900416A (en) * | 1996-02-01 | 1999-05-04 | Anthea Enterprises Incorporated | Aqueous caffeine dosage forms |
| WO2018001899A1 (en) * | 2016-06-30 | 2018-01-04 | L'oreal | Liquid mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and xanthine compound |
| FR3053334A1 (en) * | 2016-06-30 | 2018-01-05 | L'oreal | LIQUID MIXTURE CONTAINING 4- (3-ETHOXY-4-HYDROXYPHENYL) BUTAN-2-ONE AND XANTHINE COMPOUND |
| CN109414383A (en) * | 2016-06-30 | 2019-03-01 | 莱雅公司 | Liquid mixture containing 4- (3- ethyoxyl -4- hydroxyphenyl) butyl- 2- ketone and Xanthine compounds |
| US10813865B2 (en) | 2016-06-30 | 2020-10-27 | L'oreal | Liquid mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and xanthine compound |
| CN109414383B (en) * | 2016-06-30 | 2021-12-14 | 莱雅公司 | Liquid mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and xanthine compounds |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69731467T2 (en) | PROCESS FOR MAINTAINING EXISTING BODY FAT CONTENT AND / OR BODY WEIGHT | |
| DE69031285T2 (en) | Bacterial growth-promoting substance containing pullulan with or without dextran | |
| DE69301693T2 (en) | Use of a feed additive to avoid weight loss and anorexia caused by immune stimulation | |
| DE69122099T2 (en) | COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF HYPERCHOLESTERINEMIA AND CELL PROLIFERATION DISORDERS | |
| DE69322896T2 (en) | Use of proteins from the transferrin / lactoferrin family to stimulate the immune system | |
| DE69630694T2 (en) | NEUTRALIZATION OF ACID FOOD AND MEDICINAL PRODUCTS | |
| DE3040246A1 (en) | SAPONINE, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| DE60008127T2 (en) | HIGH LIPID DIET | |
| DE2521815B2 (en) | Diet food preparations and mixtures and processes for their manufacture | |
| DE3151245A1 (en) | ENTERTAINED FOOD COMPOSITION | |
| DE2813480A1 (en) | MEDICINAL DEPOT PREPARATION OF THE MULTI-UNIT DOSE TYPE | |
| DE69000663T2 (en) | ORAL AVAILABLE CALCIUM ADDITIVE FOR LIVESTOCK. | |
| DE3786893T2 (en) | Piperidine derivative for pain treatment. | |
| DE2841668A1 (en) | MEDICATED ANIMAL FEED BASED ON LIVER FLOUR | |
| DE60107272T2 (en) | IRON COMPOUNDS | |
| CH677880A5 (en) | ||
| DE3319575C2 (en) | ||
| DE2921852A1 (en) | LIPID LOWERING AGENT | |
| DE69721497T2 (en) | MULTIFUNCTIONAL FORMULATION FOR FAT ABSORPTION AND FOR REDUCING THE CHOLESTEROL CONTENT IN THE BLOOD, WHICH CONTAINS CHITOSAN AND NICOTINIC ACID | |
| DE10060750A1 (en) | Food supplement product for intestinal activation | |
| DE2111638C2 (en) | Prophylactic treatment of iron deficiency in piglets | |
| DE2559384A1 (en) | Caffeine combinations with nicotinamide - for increased solubility and lower toxicity, used in foods, medicaments and cosmetics | |
| DE69918152T2 (en) | TREATMENT OF DIGESTIVE DISORDER | |
| DE3301328A1 (en) | PRELIMINARY MEDICINAL CONTROL OF ACUTE OR CHRONIC, MYELOGENIC LEUKAEMIA | |
| DE2528460A1 (en) | USE OF L-CARBOXAMIDO-2-CYAN-AZIRIDINE AS IMMUNE STIMULANS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8139 | Disposal/non-payment of the annual fee |